Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
- PMID: 33907450
- PMCID: PMC8071080
- DOI: 10.2147/IJGM.S274568
Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
Abstract
Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are two common disorders of gut-brain interaction. Affected patients often first present to their primary care providers seeking care for symptoms of constipation, abdominal pain, and bloating, which have a significant impact on their health-related quality of life. These patients often require extensive counseling and reassurance, and knowledge of reliable diagnostic criteria and treatment options is imperative to managing their conditions. Family medicine practitioners, including nurse practitioners and physician assistants, are uniquely qualified to provide a diagnosis and safe, effective management of these disorders. This article reviews the latest evidence and provides practical advice related to diagnosis and management of IBS-C and CIC.
Keywords: advanced practice providers; chronic idiopathic constipation; constipation; irritable bowel syndrome; nurse practitioners; physician assistants.
© 2021 Patel et al.
Conflict of interest statement
Financial arrangements of the authors with companies whose products may be related to the present report are listed as follows: Sarah Patel is a consultant for Allergan plc. Elayne DeSimone is a consultant for Allergan plc. Bethany Doerfler has no conflicts to disclose. Katerine Boutros is an employee of AbbVie Inc. Samson Ng is a former employee of AbbVie Inc. and owned stock/stock options at the time of employment. Machelle Manuel is a former employee of Ironwood Pharmaceuticals, Inc., and owned stock/stock options at the time of employment. The authors report no other conflicts of interest in this work.
Figures
Similar articles
-
The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.Am J Gastroenterol. 2015 Apr;110(4):580-7. doi: 10.1038/ajg.2015.67. Epub 2015 Mar 17. Am J Gastroenterol. 2015. PMID: 25781368 Free PMC article.
-
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27. Pharmacotherapy. 2015. PMID: 26016701 Review.
-
A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.J Med Econ. 2017 Mar;20(3):273-279. doi: 10.1080/13696998.2016.1253584. Epub 2016 Nov 10. J Med Econ. 2017. PMID: 27783533 Free PMC article.
-
Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18. Neurogastroenterol Motil. 2023. PMID: 37332239 Clinical Trial.
-
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.Adv Ther. 2009 May;26(5):519-30. doi: 10.1007/s12325-009-0027-4. Epub 2009 May 14. Adv Ther. 2009. PMID: 19444393 Review.
Cited by
-
Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats.Front Pharmacol. 2022 Sep 2;13:967644. doi: 10.3389/fphar.2022.967644. eCollection 2022. Front Pharmacol. 2022. PMID: 36120292 Free PMC article.
-
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.J Manag Care Spec Pharm. 2024 Oct;30(10):1136-1148. doi: 10.18553/jmcp.2024.30.10.1136. J Manag Care Spec Pharm. 2024. PMID: 39321115 Free PMC article.
-
Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats.Nutrients. 2022 Dec 21;15(1):24. doi: 10.3390/nu15010024. Nutrients. 2022. PMID: 36615683 Free PMC article.
-
Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States.Clin Exp Gastroenterol. 2024 Aug 2;17:227-253. doi: 10.2147/CEG.S464375. eCollection 2024. Clin Exp Gastroenterol. 2024. PMID: 39114809 Free PMC article. Review.
-
Raising Expectations in IBS-C Management.Gastroenterol Hepatol (N Y). 2025 Apr;21(4):218-231. Gastroenterol Hepatol (N Y). 2025. PMID: 40416303 Free PMC article. No abstract available.
References
-
- Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110(4):580–587. doi:10.1038/ajg.2015.67 - DOI - PMC - PubMed
-
- Harris LA, Horn J, Kissous-Hunt M, Magnus L, Quigley EMM. The better understanding and recognition of the disconnects, experiences, and needs of patients with chronic idiopathic constipation (BURDEN-CIC) study: results of an online questionnaire. Adv Ther. 2017;34(12):2661–2673. doi:10.1007/s12325-017-0633-5 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous